"rationale","uuid:ID","description","instanceType","name","label","id"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","9bea2e30-4ef5-438b-b69f-1aae718b88ca","The main design for the study","StudyDesign","Study Design 1","","StudyDesign_1"
